For the latest updates on our ongoing response to COVID-19, please click here.

About Remdesivir

Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity – it is not approved anywhere globally for any use. Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19. The limited preclinical data on remdesivir in MERS and SARS indicate that remdesivir may have potential activity against COVID-19.

Remdesivir is an experimental medicine that does not have established safety or efficacy for the treatment of any condition.

Gilead’s response to COVID-19 entails three main areas: